Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Product containing precisely estropipate 1.5 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Piperazine estrone sulfate adverse reaction |
Causative agent (attribute) |
True |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing piperazine estrone sulfate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Estropipate 1.25 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Product containing precisely estropipate 625 microgram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Estropipate 750 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Estropipate 3 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Estropipate 2.5 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Estropipate 1.5mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Product containing precisely estropipate 1.5 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Product containing estropipate in oral dosage form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Product containing estropipate in vaginal dosage form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Estropipate 1.5 mg/mL vaginal cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
allergie au sulfate de pipérazine estrone |
Causative agent (attribute) |
False |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Product containing precisely estropipate 1.5 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely estropipate 1.5 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
True |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely estropipate 625 microgram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely estropipate 625 microgram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
True |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Estropipate 1.25 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Estropipate 1.25 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Estropipate 2.5 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Estropipate 2.5 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Estropipate 3 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Estropipate 3 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Estropipate 750 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Estropipate 750 microgram oral tablet |
Has basis of strength substance (attribute) |
True |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Estropipate 750 microgram oral tablet |
Has precise active ingredient |
True |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely estropipate 625 microgram/1 each conventional release oral tablet (clinical drug) |
Has precise active ingredient |
True |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Estropipate 2.5 mg oral tablet |
Has precise active ingredient |
True |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Estropipate 1.25 mg oral tablet |
Has precise active ingredient |
True |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Estropipate 3 mg oral tablet |
Has precise active ingredient |
True |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely estropipate 1.5 milligram/1 each conventional release oral tablet (clinical drug) |
Has precise active ingredient |
True |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Allergy to estropipate |
Causative agent (attribute) |
False |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Estropipate 1.5 mg/mL vaginal cream |
Has basis of strength substance (attribute) |
True |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Estropipate 1.5 mg/mL vaginal cream |
Has precise active ingredient |
True |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Estropipate only product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Estropipate-containing product in vaginal dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing only estropipate in vaginal dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Estropipate-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Estropipate only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Estropipate-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Piperazine estrone sulfate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |